New pill tested for Tough-to-Treat blood cancers
Disease control
Recruiting now
This is a first-in-human study to test the safety of a new oral drug called SGR-1505 in adults with various types of relapsed or hard-to-treat B-cell cancers, like non-Hodgkin lymphoma and chronic lymphocytic leukemia. The main goal is to find the highest dose patients can tolera…
Phase: PHASE1 • Sponsor: Schrödinger, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC